Latest Melanoma Stories

Lawrence LeBlond for redOrbit.com - Your Universe Online Got Melanoma? There’s an app for that. But I wouldn’t rely too heavily on what it might be telling you. According to a new report, published Online First in JAMA Dermatology, smartphone apps claiming to diagnose deadly melanoma cancers have wrongly dismissed almost 25 percent of suspicious moles. And the inaccurate test results could result in life-threatening delays in visiting a healthcare professional to get necessary...

Boca Raton Facial Plastic Surgeon to Participate in Benefit Run for the Melanoma Foundation of New England Boca Raton, FL (PRWEB) January 15, 2013 Renowned Boca Raton facial plastic surgeon Dr. Nathan E. Nachlas is excited to participate in the Run from the Rays 5K Race to benefit the Melanoma Foundation of New England. Run from the Rays is a 5K race which will be held on April 21, 2013, to benefit the Melanoma Foundation of New England and other non-profit organizations dedicated to the...

SAN DIEGO, Jan. 15, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced the company's upcoming milestones for 2013 at the Biotech Showcase conference held January 7-9 in San Francisco, CA. (Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO) "2012 marked a critical year for OncoSec," said Punit Dhillon, President and CEO. "We...

BMJ Editor says all trials must be registered and the results published A special report published by the BMJ today finds that thousands of melanoma patients around the world are undergoing an expensive and invasive procedure called sentinel node biopsy, despite a lack of clear evidence and concerns that it may do more harm than good. Although not recommended for routine use in England, it has become the standard care for melanoma patients in several countries including the United...

LOS ANGELES, Jan. 8, 2013 /PRNewswire/ -- On Saturday February 16, 2013, Suzanne DeLaurentiis will produce a private gifting event in honor of the upcoming Oscars. The event is sponsored by the Melanoma Research Foundation and Proteg-GO. Proceeds raised from the event will benefit the Melanoma Foundation. Donations from the door will benefit the Marine Corp Association. The gifting event will take place at the Century City Hyatt from 11am-2pm. Guests of the gifting lounge will be...

Diagnostic pathology firm to offer breakthrough prostate cancer assay to urology market THUNDER BAY, ON, Jan. 7, 2013 /PRNewswire/ - Mitomics, a developer of mitochondrial DNA-based tests for early disease detection, today announced it has entered into a sales and marketing agreement for the Prostate Core Mitomic Test((TM)) (PCMT(TM)) with Sterling Pathology National Laboratories. Under the agreement, Sterling Pathology National Laboratories, a leader in diagnostic pathology...

After recently announcing success in eliminating melanoma metastasis in laboratory experiments, scientists at Virginia Commonwealth University Massey Cancer Center have made another important discovery in understanding the process by which the gene mda-9/syntenin contributes to metastasis in melanoma (the spread of skin cancer) and possibly a variety of other cancers. Published in the journal Cancer Research, the study demonstrated that mda-9/syntenin is a key regulator of angiogenesis,...

DALLAS, Jan. 3, 2013 /PRNewswire/ -- Gradalis, Inc. today announced that is has closed a $24 million Series B round of financing. Gradalis will use the funding to advance its autologous vaccine platform, FANG(TM), through late-stage clinical trials and expand manufacturing capabilities to accommodate commercial launch of FANG. In addition, the funding will be used to progress the clinical and preclinical development of the company's bifunctional shRNA platform. "The boost that...

NEW YORK, Jan. 3, 2013 /PRNewswire/ -- MELA Sciences, Inc. (NASDAQ: MELA), the medical device company that developed MelaFind®, a breakthrough device intended to help dermatologists detect melanoma when it is still curable, announced today that it has named Rpr Marketing Communications as its U.S. public relations agency of record. (Logo: http://photos.prnewswire.com/prnh/20130103/NY36051LOGO ) "This partnership is a natural fit given both companies' unique expertise in skin cancer...

SAN DIEGO, Jan. 3, 2013 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a developer of transrenal molecular diagnostics, announced that it has entered into a clinical collaboration with The University of Texas MD Anderson Cancer Center to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers. (Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO) Researchers will use Trovagene's proprietary transrenal DNA (TrDNA) detection...